Calliditas Therapeutics Past Earnings Performance
Past criteria checks 0/6
Calliditas Therapeutics's earnings have been declining at an average annual rate of -25.5%, while the Pharmaceuticals industry saw earnings declining at 0.4% annually. Revenues have been growing at an average rate of 61.3% per year.
Key information
-25.5%
Earnings growth rate
-20.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 61.3% |
| Return on equity | -436.8% |
| Net Margin | -40.0% |
| Next Earnings Update | 13 Aug 2024 |
Recent past performance updates
Recent updates
Asahi Kasei To Pay A Fair Price For Calliditas Therapeutics
May 28Calliditas Therapeutics GAAP EPS of -SEK 3.62, revenue of SEK 64M
Aug 18Calliditas Therapeutics wins European approval for Kinpeygo for IgA nephropathy
Jul 15Calliditas submits nefecon marketing authorisation application to the EMA
May 28Calliditas shares rise 10% as FDA grants priority review for Nefecon
Apr 28Calliditas Therapeutics reports Q3 results
Nov 12Revenue & Expenses Breakdown
How Calliditas Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 1,311 | -525 | 1,163 | 526 |
| 31 Dec 23 | 1,207 | -466 | 1,061 | 502 |
| 30 Sep 23 | 1,184 | -451 | 1,040 | 498 |
| 30 Jun 23 | 1,150 | -292 | 968 | 421 |
| 31 Mar 23 | 944 | -393 | 872 | 428 |
| 31 Dec 22 | 803 | -412 | 775 | 415 |
| 30 Sep 22 | 405 | -628 | 653 | 413 |
| 30 Jun 22 | 343 | -608 | 562 | 402 |
| 31 Mar 22 | 279 | -576 | 474 | 381 |
| 31 Dec 21 | 229 | -500 | 390 | 357 |
| 30 Sep 21 | 199 | -452 | 302 | 331 |
| 30 Jun 21 | 0 | -600 | 248 | 304 |
| 31 Mar 21 | 0 | -501 | 182 | 277 |
| 31 Dec 20 | 1 | -433 | 142 | 241 |
| 30 Sep 20 | 47 | -286 | 102 | 209 |
| 30 Jun 20 | 47 | -198 | 71 | 190 |
| 31 Mar 20 | 185 | -54 | 71 | 173 |
| 31 Dec 19 | 185 | -33 | 63 | 150 |
| 30 Sep 19 | 138 | -54 | 47 | 142 |
| 30 Jun 19 | 138 | -35 | 44 | 120 |
| 31 Mar 19 | 0 | -136 | 33 | 99 |
| 31 Dec 18 | 0 | -132 | 31 | 99 |
| 30 Sep 18 | 0 | -128 | 64 | 65 |
| 30 Jun 18 | 0 | -115 | 74 | 41 |
| 31 Mar 18 | 0 | -113 | 81 | 31 |
| 31 Dec 17 | 0 | -87 | 85 | 0 |
| 31 Dec 16 | 0 | -57 | 56 | 0 |
Quality Earnings: CALT is currently unprofitable.
Growing Profit Margin: CALT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CALT is unprofitable, and losses have increased over the past 5 years at a rate of 25.5% per year.
Accelerating Growth: Unable to compare CALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CALT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.9%).
Return on Equity
High ROE: CALT has a negative Return on Equity (-436.8%), as it is currently unprofitable.